Topical imiquimod to treat recurrent breast cancer

Breast Cancer Research and Treatment

Volumn 94, Issue 1, 2005, Pages 93-94

  Hengge, Ulrich R ^a   Roth, Stephan ^a   Tannapfel, Andrea ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; IMMUNOMODULATING AGENT;

ADULT; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COBALT TELETHERAPY; EROSION; ERYTHEMA; FEMALE; GAMMA RADIATION; HUMAN; LETTER; MASTECTOMY; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; SKIN NEOPLASMS;

EID: 26244456936     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-7017-2     Document Type: Letter

References (5)

1. HJ Burstein K Polyak JS Wong SC Lester CM Kaelin 2004 Ductal carcinoma in situ of the breast. N Engl J Med 350 1430 1441
2. KW Barber MB Dockerty OT Clagett 1961 Inflammatory carcinoma of the breast. Surg Gynec Obstet 112 406 410
3. UR Hengge B Benninghoff T Ruzicka M Goos 2001 Topical immunomodulators - progress towards treating inflammation, infection and cancer? Lancet Infect Dis 1 189 198
4. S Nair C McLaughlin A Weizer Z Su D Boczkowski J Dannull J Vieweg E Gilboa 2003 Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171 6275 6282
5. M Shackleton ID Davis W Hopkins 2004 The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immunity 4 9